HC Wainwright Has Bearish Estimate for ACAD FY2027 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Investment analysts at HC Wainwright decreased their FY2027 EPS estimates for shares of ACADIA Pharmaceuticals in a report issued on Friday, September 25th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will earn $1.87 per share for the year, down from their previous forecast of $1.89. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.64 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.93 EPS, FY2029 earnings at $3.26 EPS and FY2030 earnings at $3.40 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The firm had revenue of $308.00 million during the quarter, compared to the consensus estimate of $296.55 million. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. ACADIA Pharmaceuticals’s revenue was up 16.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.16 earnings per share.

Several other research analysts have also weighed in on ACAD. BMO Capital Markets cut their target price on ACADIA Pharmaceuticals from $36.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, September 24th. UBS Group upped their price target on ACADIA Pharmaceuticals from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. TD Cowen restated a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 24th. Canaccord Genuity Group lifted their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Citizens Jmp reduced their price objective on ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating on the stock in a research note on Friday, September 25th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.76.

ACADIA Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ ACAD opened at $20.22 on Tuesday. The stock has a market capitalization of $3.48 billion, a PE ratio of 9.11 and a beta of 0.86. The firm has a fifty day moving average of $27.31 and a 200-day moving average of $24.17. ACADIA Pharmaceuticals has a 52-week low of $19.69 and a 52-week high of $30.96.

Institutional Trading of ACADIA Pharmaceuticals

Several large investors have recently bought and sold shares of ACAD. Nykredit A S acquired a new stake in ACADIA Pharmaceuticals during the 2nd quarter valued at $38,000. Integrated Wealth Concepts LLC purchased a new stake in ACADIA Pharmaceuticals during the 2nd quarter worth $50,000. Global Retirement Partners LLC acquired a new position in ACADIA Pharmaceuticals in the 2nd quarter worth $64,000. GAMMA Investing LLC lifted its holdings in ACADIA Pharmaceuticals by 15.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 402 shares in the last quarter. Finally, Transamerica Financial Advisors LLC purchased a new position in ACADIA Pharmaceuticals in the 2nd quarter valued at about $104,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Insider Transactions at ACADIA Pharmaceuticals

In other news, EVP Elizabeth Thompson sold 16,558 shares of the company’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the sale, the executive vice president owned 18,994 shares of the company’s stock, valued at $496,313.22. This represents a 46.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mark Schneyer sold 14,292 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $29.22, for a total value of $417,612.24. Following the completion of the sale, the executive vice president directly owned 67,828 shares of the company’s stock, valued at $1,981,934.16. The trade was a 17.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 36,699 shares of company stock worth $1,019,894. 26.20% of the stock is currently owned by insiders.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering weight-banded dosing of trofinetide, the active ingredient in Daybue for Rett syndrome. The patent is expected to extend U.S. protection through March 2041, supporting a longer commercial runway and potentially limiting generic competition. Acadia Announces Trofinetide Patent Allowance
• Positive Sentiment: Analyst coverage continues to reflect confidence in Acadia’s longer-term growth: HC Wainwright maintained a Buy rating and a $33 price target, while projecting rising EPS from $1.87 in fiscal 2027 to $3.40 in fiscal 2030. HC Wainwright ACAD Earnings Estimate
• Neutral Sentiment: HC Wainwright made small downward revisions to its fiscal 2027–2030 EPS estimates, trimming forecasts by $0.02 per share in each year. The reductions are modest, but suggest slightly lower expectations for future profitability despite the continued Buy rating.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of ACADIA investors. The announcement does not establish wrongdoing, but shareholder investigations can add reputational and legal uncertainty and pressure sentiment. Pomerantz ACAD Investor Alert
• Negative Sentiment: Unusually heavy put-option activity indicated increased bearish positioning: traders purchased 6,078 puts, about 323% above average daily volume, with puts substantially outnumbering calls. ACAD Put Options Activity

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for neurological and psychiatric disorders. The company is headquartered in San Diego, California, and conducts research and commercial activities primarily in the United States.

ACADIA’s marketed products include NUPLAZID (pimavanserin), an atypical antipsychotic approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also markets DAYBUE (trofinetide), a therapy for Rett syndrome, a rare neurodevelopmental disorder.

Founded in 1993, ACADIA continues to advance a pipeline of therapies for central nervous system conditions, including additional neurological and psychiatric disorders.